Forensic Analysis · Healthcare / Pharmaceuticals / Biotech · as of Aug 12, 2026
Bioage Labs, Inc. (BIOA)
A forensic read on Bioage Labs, Inc. built from its complete SEC filings — financial-health screens, earnings quality, red flags and a price-aware rating. Reproducible math, not opinion.
D · Weak — demands caution
Forensic grade
Grey Zone
Financial health
12.7
Distress distance
Not computable
Earnings quality
3
Forensic signals
-4.9
P / E (ttm)
-29.6%
ROE
$490M
Market cap
0.00%
Dividend yield
91.0%
Revenue growth
This free snapshot doesn't read filing or proxy text, so the auditor-quality and governance checks that can lower a grade were not evaluated (red flags, auditor quality, say on pay, board independence). Those checks only ever lower a grade, so the full analysis can land below the grade above but never above it — treat it as the most favourable reading, not the settled one.
Bioage Labs, Inc. earns a D (Weak — demands caution) forensic quality grade, and its balance-sheet distress test reads 12.7, placing it in the Grey zone. 3 forensic signals were flagged in its latest SEC filings, led by accruals ratio (% of noa).
What the filings flag
n/m (sign flip)
FY2024→FY2025
Accruals ratio (% of NOA).Net operating assets flipped from negative to positive FY2024→FY2025 (FY2024 $-22.7M to FY2025 $+85.8M) — the standard accruals ratio divides by the average of the two, which collapses toward zero right as the sign changes, so the resulting percentage is a denominator artifact, not a real accrual measurement. Treat this as a structural balance-sheet shift to understand on its own terms rather than a clean or dirty accruals read.
n/m (stock split)
FY2024–FY2025
Share count (stock split).Diluted share count changed +235% over the last 1 year to FY2025, but that includes a large one-time change around FY2025 consistent with a stock split or reverse split, not gradual buybacks or issuance — a split changes the count with NO effect on any holder's proportional ownership, so the raw +235.0%/yr figure isn't a real buyback/dilution read here.
130% of rev
FY2025
Stock-based comp load.Stock-based compensation ran 130% of revenue in FY2025 — about $0.33 per diluted share. It is a real cost, but it is not a cash cost — no cash left the business, which is why operating cash flow adds it back. The bill lands on the share count instead, and this filer's count is not on file in enough years to say how much of the company changed hands to pay it.
Key fundamentals
Latest Revenue$9.0M
Net Margin-896.1%
Free Cash Flow-$82.3M
Return on Equity-29.6%
Debt / Equity0.01x
The forensic grade and screens above are free — no account needed. Want the AI investment read on top — the 0–100 rating, thesis, bull-vs-bear, red flags and the 12-month scenario, written from Bioage Labs, Inc.'s actual 10-K/10-Q/8-K filings?